Skip to main content
Fig. 1 | Epigenetics & Chromatin

Fig. 1

From: Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells

Fig. 1

Transcriptional and translational data after 5-azadC treatment. The upper panel reports the scheme of 5-azadC treatment with the relative time points. Relative quantification of FMR1-mRNA by RT-PCR after two independent treatments (n = 2) with 5-azadC of FXS1 (a) and FXS2 (b) cell lines showed increased FMR1-mRNA expression at T2–T3, decreasing at T6 and T7. The reactivation pattern in WT1 cell line was substantially unmodified after 5-azadC treatment (c). The transcriptional reactivation levels are expressed in percentage of the untreated WT cell line, arbitrarily set at 100 %. Western blot with antibody against FMRP and GAPDH on FXS1 and FXS2 cell extracts showed that after 7-day treatment with 5-azadC (T1) the expression of FMRP was restored and disappeared after 22 days (T7) from the end of the treatment. After 5-azadC treatment FMRP levels did not reach those of untreated WT

Back to article page